Search

Your search keyword '"Cerbai, Elisabetta"' showing total 381 results
Start Over Author "Cerbai, Elisabetta" Search Limiters Full Text
381 results on '"Cerbai, Elisabetta"'

1. Slower Calcium Handling Balances Faster Crossbridge Cycling in Human MYBPC3 HCM

Author

Pioner, Josè Manuel, Vitale, Giulia, Steczina, Sonette, Langione, Marianna, Margara, Francesca, Santini, Lorenzo, Giardini, Francesco, Lazzeri, Erica, Piroddi, Nicoletta, Scellini, Beatrice, Palandri, Chiara, Schuldt, Maike, Spinelli, Valentina, Girolami, Francesca, Mazzarotto, Francesco, van der Velden, Jolanda, Cerbai, Elisabetta, Tesi, Chiara, Olivotto, Iacopo, Bueno-Orovio, Alfonso, Sacconi, Leonardo, Coppini, Raffaele, Ferrantini, Cecilia, Regnier, Michael, and Poggesi, Corrado

Published
2023
Full Text
View/download PDF

2. Systematic large-scale assessment of the genetic architecture of left ventricular noncompaction reveals diverse etiologies

Author

Mazzarotto, Francesco, Hawley, Megan H., Beltrami, Matteo, Beekman, Leander, de Marvao, Antonio, McGurk, Kathryn A., Statton, Ben, Boschi, Beatrice, Girolami, Francesca, Roberts, Angharad M., Lodder, Elisabeth M., Allouba, Mona, Romeih, Soha, Aguib, Yasmine, Baksi, A. John, Pantazis, Antonis, Prasad, Sanjay K., Cerbai, Elisabetta, Yacoub, Magdi H., O’Regan, Declan P., Cook, Stuart A., Ware, James S., Funke, Birgit, Olivotto, Iacopo, Bezzina, Connie R., Barton, Paul J. R., and Walsh, Roddy

Published
2021
Full Text
View/download PDF

3. Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study

Author

Coppini, Raffaele, Ferrantini, Cecilia, Pioner, Josè Manuel, Santini, Lorenzo, Wang, Zhinuo J., Palandri, Chiara, Scardigli, Marina, Vitale, Giulia, Sacconi, Leonardo, Stefàno, Pierluigi, Flink, Laura, Riedy, Katherine, Pavone, Francesco Saverio, Cerbai, Elisabetta, Poggesi, Corrado, Mugelli, Alessandro, Bueno-Orovio, Alfonso, Olivotto, Iacopo, and Sherrid, Mark V.

Published
2019
Full Text
View/download PDF

4. Cardiac safety assessment of a novel recombinant bispecific antibody targeting the ether-à-go-go related gene 1 (hERG1)-β1 integrin macromolecular complex

Author

Santini, Lorenzo, primary, Duranti, Claudia, additional, Palandri, Chiara, additional, Giammarino, Lucrezia, additional, Musumeci, Monica, additional, Carlucci, Lucia, additional, Capitani, Chiara, additional, Colasurdo, Rossella, additional, Recchia, Fabio, additional, Cerbai, Elisabetta, additional, Coppini, Raffaele, additional, and Arcangeli, Annarosa, additional

Published
2023
Full Text
View/download PDF

5. Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center

Author

Mazzarotto, Francesco, Girolami, Francesca, Boschi, Beatrice, Barlocco, Fausto, Tomberli, Alessia, Baldini, Katia, Coppini, Raffaele, Tanini, Ilaria, Bardi, Sara, Contini, Elisa, Cecchi, Franco, Pelo, Elisabetta, Cook, Stuart A., Cerbai, Elisabetta, Poggesi, Corrado, Torricelli, Francesca, Walsh, Roddy, and Olivotto, Iacopo

Published
2019
Full Text
View/download PDF

6. Content of mitochondrial calcium uniporter (MCU) in cardiomyocytes is regulated by microRNA-1 in physiologic and pathologic hypertrophy

Author

Zaglia, Tania, Ceriotti, Paola, Campo, Antonio, Borile, Giulia, Armani, Andrea, Carullo, Pierluigi, Prando, Valentina, Coppini, Raffaele, Vida, Vladimiro, Stølen, Tomas O., Ulrik, Wisløff, Cerbai, Elisabetta, Stellin, Giovanni, Faggian, Giuseppe, De Stefani, Diego, Sandri, Marco, Rizzuto, Rosario, Di Lisa, Fabio, Pozzan, Tullio, Catalucci, Daniele, and Mongillo, Marco

Published
2017

8. Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human MYBPC3 HCM

Author

Pioner, Josè Manuel, primary, Vitale, Giulia, additional, Steczina, Sonette, additional, Langione, Marianna, additional, Margara, Francesca, additional, Santini, Lorenzo, additional, Giardini, Francesco, additional, Lazzeri, Erica, additional, Piroddi, Nicoletta, additional, Scellini, Beatrice, additional, Palandri, Chiara, additional, Schuldt, Maike, additional, Spinelli, Valentina, additional, Girolami, Francesca, additional, Mazzarotto, Francesco, additional, van der Velden, Jolanda, additional, Cerbai, Elisabetta, additional, Tesi, Chiara, additional, Olivotto, Iacopo, additional, Bueno-Orovio, Alfonso, additional, Sacconi, Leonardo, additional, Coppini, Raffaele, additional, Ferrantini, Cecilia, additional, Regnier, Michael, additional, and Poggesi, Corrado, additional

Published
2023
Full Text
View/download PDF

9. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022

Author

Tamargo, Juan, Agewall, Stefan, Borghi, Claudio, Ceconi, Claudio, Cerbai, Elisabetta, Dan, Gheorghe A, Ferdinandy, Péter, Grove, Erik Lerkevang, Rocca, Bianca, Sulzgruber, Patrick, Semb, Anne Grete, Sossalla, Samuel, Niessner, Alexander, Kaski, Juan Carlo, Dobrev, Dobromir, Rocca, Bianca (ORCID:0000-0001-8304-6423), Tamargo, Juan, Agewall, Stefan, Borghi, Claudio, Ceconi, Claudio, Cerbai, Elisabetta, Dan, Gheorghe A, Ferdinandy, Péter, Grove, Erik Lerkevang, Rocca, Bianca, Sulzgruber, Patrick, Semb, Anne Grete, Sossalla, Samuel, Niessner, Alexander, Kaski, Juan Carlo, Dobrev, Dobromir, and Rocca, Bianca (ORCID:0000-0001-8304-6423)

Abstract

Cardiovascular diseases (CVD) remain the leading cause of death worldwide, and pharmacotherapy of most of them is suboptimal. Thus, there is a clear unmet clinical need to develop new pharmacological strategies with greater efficacy and better safety profiles. In this review, we summarize the most relevant advances in cardiovascular pharmacology in 2022, including the approval of first-in-class drugs that open new avenues for the treatment of obstructive hypertrophic cardiomyopathy (mavacamten), type 2 diabetes mellitus (tirzepatide), and heart failure (HF) independent of left ventricular ejection fraction (sodium-glucose cotransporter 2 inhibitors). We also dealt with fixed dose combination therapies repurposing different formulations of 'old' drugs with well-known efficacy and safety for the treatment of patients with acute decompensated HF (acetazolamide plus loop diuretics), atherosclerotic cardiovascular disease (moderate-dose statin plus ezetimibe), Marfan syndrome (angiotensin receptor blockers plus beta-blockers), and secondary cardiovascular prevention (i.e. low-dose aspirin, ramipril, and atorvastatin), thereby filling existing gaps in knowledge and opening new avenues for the treatment of CVD. Clinical trials confirming the role of dapagliflozin in patients with HF and mildly reduced or preserved ejection fraction, long-term evolocumab to reduce the risk of cardiovascular events, vitamin K antagonists for stroke prevention in patients with rheumatic heart disease-associated atrial fibrillation, antibiotic prophylaxis in patients at high risk for infective endocarditis before invasive dental procedures, and vutrisiran for the treatment of hereditary transthyretin-related amyloidosis with polyneuropathy were also reviewed. Finally, we briefly discuss recent clinical trials suggesting that FXIa inhibitors may have the potential to uncouple thrombosis from haemostasis and attenuate/prevent thromboembolic events with minimal disruption of haemostasis.

Published
2023

11. Genetic characterization of juvenile sudden cardiac arrest and death in Tuscany: The ToRSADE registry

Author

Girolami, Francesca, primary, Spinelli, Valentina, additional, Maurizi, Niccolò, additional, Focardi, Martina, additional, Nesi, Gabriella, additional, Maio, Vincenza, additional, Grifoni, Rossella, additional, Albora, Giuseppe, additional, Bertaccini, Bruno, additional, Targetti, Mattia, additional, Coppini, Raffaele, additional, Favilli, Silvia, additional, Olivotto, Iacopo, additional, and Cerbai, Elisabetta, additional

Published
2022
Full Text
View/download PDF

13. Calcium handling maturation and adaptation to increased substrate stiffness in human iPSC-derived cardiomyocytes: The impact of full-length dystrophin deficiency

Author

Pioner, Josè Manuel, primary, Santini, Lorenzo, additional, Palandri, Chiara, additional, Langione, Marianna, additional, Grandinetti, Bruno, additional, Querceto, Silvia, additional, Martella, Daniele, additional, Mazzantini, Costanza, additional, Scellini, Beatrice, additional, Giammarino, Lucrezia, additional, Lupi, Flavia, additional, Mazzarotto, Francesco, additional, Gowran, Aoife, additional, Rovina, Davide, additional, Santoro, Rosaria, additional, Pompilio, Giulio, additional, Tesi, Chiara, additional, Parmeggiani, Camilla, additional, Regnier, Michael, additional, Cerbai, Elisabetta, additional, Mack, David L., additional, Poggesi, Corrado, additional, Ferrantini, Cecilia, additional, and Coppini, Raffaele, additional

Published
2022
Full Text
View/download PDF

17. Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease:A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

Author

Tamargo, Juan, Kjeldsen, Keld Per, Delpon, Eva, Semb, Anne Grete, Cerbai, Elisabetta, Dobrev, Dobromir, Savarese, Gianluigi, Sulzgruber, Patrick, Rosano, Giuseppe, Borghi, Claudio, Wassman, Seven, Torp-Pedersen, Christian Tobias, Agewall, Stefan, Drexel, Heinz, Baumgartner, Iris, Lewis, Basil, Ceconi, Claudio, Kaski, Juan Carlos, Niessner, Alexander, Tamargo, Juan, Kjeldsen, Keld Per, Delpon, Eva, Semb, Anne Grete, Cerbai, Elisabetta, Dobrev, Dobromir, Savarese, Gianluigi, Sulzgruber, Patrick, Rosano, Giuseppe, Borghi, Claudio, Wassman, Seven, Torp-Pedersen, Christian Tobias, Agewall, Stefan, Drexel, Heinz, Baumgartner, Iris, Lewis, Basil, Ceconi, Claudio, Kaski, Juan Carlos, and Niessner, Alexander

Abstract

Population ageing has resulted in an increasing number of older people living with chronic diseases (multimorbidity) requiring five or more medications daily (polypharmacy). Ageing produces important changes in the cardiovascular system and represents the most potent single cardiovascular risk factor. Cardiovascular diseases (CVDs) constitute the greatest burden for older people, their caregivers, and healthcare systems. Cardiovascular pharmacotherapy in older people is complex because age-related changes in body composition, organ function, homeostatic mechanisms, and comorbidities modify the pharmacokinetic and pharmacodynamic properties of many commonly used cardiovascular and non-cardiovascular drugs. Additionally, polypharmacy increases the risk of adverse drug reactions and drug interactions, which in turn can lead to increased morbi-mortality and healthcare costs. Unfortunately, evidence of drug efficacy and safety in older people with multimorbidity and polypharmacy is limited because these individuals are frequently underrepresented/excluded from clinical trials. Moreover, clinical guidelines are largely written with a single-disease focus and only occasionally address the issue of coordination of care, when and how to discontinue treatments, if required, or how to prioritize recommendations for patients with multimorbidity and polypharmacy. This review analyses the main challenges confronting healthcare professionals when prescribing in older people with CVD, multimorbidity, and polypharmacy. Our goal is to provide information that can contribute to improving drug prescribing, efficacy, and safety, as well as drug adherence and clinical outcomes.

Published
2022

19. Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy

Author

Coppini, Raffaele, Mazzoni, Luca, Ferrantini, Cecilia, Gentile, Francesca, Pioner, Josè Manuel, Laurino, Annunziatina, Santini, Lorenzo, Bargelli, Valentina, Rotellini, Matteo, Bartolucci, Gianluca, Crocini, Claudia, Sacconi, Leonardo, Tesi, Chiara, Belardinelli, Luiz, Tardiff, Jil, Mugelli, Alessandro, Olivotto, Iacopo, Cerbai, Elisabetta, and Poggesi, Corrado

Published
2017
Full Text
View/download PDF

21. Sex‐Related Differences in Genetic Cardiomyopathies

Author

Argirò, Alessia, primary, Ho, Carolyn, additional, Day, Sharlene M., additional, van der Velden, Jolanda, additional, Cerbai, Elisabetta, additional, Saberi, Sara, additional, Tardiff, Jil C., additional, Lakdawala, Neal K., additional, and Olivotto, Iacopo, additional

Published
2022
Full Text
View/download PDF

22. Paradoxical prolongation of QT interval during exercise in patients with hypertrophic cardiomyopathy: cellular mechanisms and implications for diastolic function

Author

Coppini, Raffaele, primary, Beltrami, Matteo, additional, Doste, Ruben, additional, Bueno-Orovio, Alfonso, additional, Ferrantini, Cecilia, additional, Vitale, Giulia, additional, Pioner, Josè Manuel, additional, Santini, Lorenzo, additional, Argirò, Alessia, additional, Berteotti, Martina, additional, Mori, Fabio, additional, Marchionni, Niccolò, additional, Stefàno, Pierluigi, additional, Cerbai, Elisabetta, additional, Poggesi, Corrado, additional, and Olivotto, Iacopo, additional

Published
2022
Full Text
View/download PDF

23. Genotype-Driven Pathogenesis of Atrial Fibrillation in Hypertrophic Cardiomyopathy: The Case of Different TNNT2 Mutations

Author

Pioner, Josè Manuel, primary, Vitale, Giulia, additional, Gentile, Francesca, additional, Scellini, Beatrice, additional, Piroddi, Nicoletta, additional, Cerbai, Elisabetta, additional, Olivotto, Iacopo, additional, Tardiff, Jil, additional, Coppini, Raffaele, additional, Tesi, Chiara, additional, Poggesi, Corrado, additional, and Ferrantini, Cecilia, additional

Published
2022
Full Text
View/download PDF

24. Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease : A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

Author

Tamargo, Juan, Kjeldsen, Keld Per, Delpón, Eva, Semb, Anne Grete, Cerbai, Elisabetta, Dobrev, Dobromir, Savarese, Gianluigi, Sulzgruber, Patrick, Rosano, Giuseppe, Borghi, Claudio, Wassman, Seven, Torp-Pedersen, Christian Tobias, Agewall, Stefan, Drexel, Heinz, Baumgartner, Iris, Lewis, Basil, Ceconi, Claudio, Kaski, Juan Carlos, and Niessner, Alexander

Subjects
Medizin
Abstract

Population ageing has resulted in an increasing number of older people living with chronic diseases (multimorbidity) requiring five or more medications daily (polypharmacy). Ageing produces important changes in the cardiovascular system and represents the most potent single cardiovascular risk factor. Cardiovascular diseases (CVDs) constitute the greatest burden for older people, their caregivers, and healthcare systems. Cardiovascular pharmacotherapy in older people is complex because age-related changes in body composition, organ function, homeostatic mechanisms, and comorbidities modify the pharmacokinetic and pharmacodynamic properties of many commonly used cardiovascular and non-cardiovascular drugs. Additionally, polypharmacy increases the risk of adverse drug reactions and drug interactions, which in turn can lead to increased morbi-mortality and healthcare costs. Unfortunately, evidence of drug efficacy and safety in older people with multimorbidity and polypharmacy is limited because these individuals are frequently underrepresented/excluded from clinical trials. Moreover, clinical guidelines are largely written with a single-disease focus and only occasionally address the issue of coordination of care, when and how to discontinue treatments, if required, or how to prioritize recommendations for patients with multimorbidity and polypharmacy. This review analyses the main challenges confronting healthcare professionals when prescribing in older people with CVD, multimorbidity, and polypharmacy. Our goal is to provide information that can contribute to improving drug prescribing, efficacy, and safety, as well as drug adherence and clinical outcomes.

Published
2022

27. Acute appendicitis in a patient immunised with COVID‐19 vaccine: A case report with morphological analysis.

Author

Marconi, Ettore, Crescioli, Giada, Bonaiuti, Roberto, Pugliese, Lavinia, Santi, Raffaella, Nesi, Gabriella, Cerbai, Elisabetta, Vannacci, Alfredo, and Lombardi, Niccolò

Subjects
COVID-19, COVID-19 vaccines, APPENDICITIS, COVID-19 pandemic, COMPUTED tomography
Abstract

Although the benefit/risk profile for mRNA COVID‐19 vaccines is recognised as extremely favourable, appendicitis is currently considered an adverse event (AE) of special interest. We describe the case of a 58‐year‐old female who presented with signs and symptoms of appendicitis approximately 48 hours after her first injection of the Pfizer‐BioNTech vaccine. Abdominal ultrasound revealed fluid collection in the right iliac fossa and cecal wall thickening. Following the surgical visit, CT scan with contrast showed a distended appendix with thickened walls, suggestive of acute appendicitis. The patient tested negative to upper respiratory COVID‐19 reverse transcription‐polymerase chain reaction. Clinical trials and observational studies suggest a possible association between appendicitis and COVID‐19 vaccines. Th‐1 driven granulomatous inflammation reported in our case represents an infrequent nonspecific chronic inflammation of the appendix, especially in the setting of delayed or interval appendectomy. In view of the current paediatric vaccination campaign, we recommend monitoring the safety profile and potential gastrointestinal AEs associated with mRNA COVID‐19 vaccines to swiftly manage subjects with gastrointestinal symptoms and prevent potential complications. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Edward Carmeliet (1930–2021)—channelling scientific curiosity: a tribute from the ESC Working Group on Cardiac Cellular Electrophysiology

Author

Ravens, Ursula, primary, Gomez, Ana M, additional, Heijman, Jordi, additional, Remme, Carol Ann, additional, Dobrev, Dobromir, additional, Smith, Godfrey, additional, Volders, Paul G A, additional, Cerbai, Elisabetta, additional, Eisner, David A, additional, Casadei, Barbara, additional, Zaza, Antonio, additional, Richard, Sylvain, additional, Mugelli, Alessandro, additional, Vassort, Guy, additional, Brown, Hilary F, additional, and Sipido, Karin R, additional

Published
2021
Full Text
View/download PDF

34. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week

Author

Emdin, Michele, Aimo, Alberto, Castiglione, Vincenzo, Vergaro, Giuseppe, Georgiopoulos, Georgios, Saccaro, Luigi Francesco, Lombardi, Carlo Mario, Passino, Claudio, Cerbai, Elisabetta, Metra, Marco, Senni, Michele, Emdin, M, Aimo, A, Castiglione, V, Vergaro, G, Georgiopoulos, G, Saccaro, L, Lombardi, C, Passino, C, Cerbai, E, Metra, M, and Senni, M

Subjects
cGMP, Angiotensin Receptor Antagonists, Treatment Outcome, heart failure, natriuretic peptides, sGC, vericiguat, Guanosine Monophosphate, Heart Failure, Humans, Stroke Volume, natriuretic peptide
Abstract

The significant morbidity and mortality associated with heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF) justify the search for novel therapeutic agents. Reduced cyclic guanosine monophosphate levels contribute to HF progression. Among molecules modulating the nitric oxide (NO)-GMP-phosphodiesterase (PDE) pathway, the evaluation of nitrates, synthetic natriuretic peptides (NP), and NP analogs has yielded mixed results. Conversely, sacubitril/valsartan, combining NP degradation inhibition through neprilysin and angiotensin receptor blockade, has led to groundbreaking findings in HFrEF. Other strategies to increase tissue cyclic guanosine monophosphate have been attempted, such as PDE-3 or PDE-5 inhibition (with negative or neutral results), NO-independent soluble guanylate cyclase (sGC) activation, or enhancement of sGC sensitivity to endogenous NO. Following the positive results of the phase 3 VICTORIA (A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction) trial on the sGC stimulator vericiguat in HFrEF, the main open questions are the efficacy of the sacubitril/valsartan-vericiguat combination in HFrEF and of vericiguat in HFpEF.

Published
2020

35. Mechanisms of pro-arrhythmic abnormalities in ventricular repolarisation and anti-arrhythmic therapies in human hypertrophic cardiomyopathy

Author

Passini, Elisa, Mincholé, Ana, Coppini, Raffaele, Cerbai, Elisabetta, Rodriguez, Blanca, Severi, Stefano, Bueno-Orovio, Alfonso, Passini, Elisa, Mincholé, Ana, Coppini, Raffaele, Cerbai, Elisabetta, Rodriguez, Blanca, Severi, Stefano, and Bueno-Orovio, Alfonso

Subjects
Pro-arrhythmic mechanism, Calcium Channels, L-Type, Heart Ventricles, Repolarization reserve, Action Potentials, Arrhythmias, Cardiac, Cardiomyopathy, Hypertrophic, Pro-arrhythmic mechanisms, Inter-subject variability, Calcium Channel Blockers, Models, Biological, Sodium-Calcium Exchanger, Electrophysiological Phenomena, Hypertrophic cardiomyopathy, Humans, Calcium, Myocytes, Cardiac, Original Article, Cardiology and Cardiovascular Medicine, Anti-Arrhythmia Agents, Molecular Biology, In silico drug testing
Abstract

Introduction Hypertrophic cardiomyopathy (HCM) is a cause of sudden arrhythmic death, but the understanding of its pro-arrhythmic mechanisms and an effective pharmacological treatment are lacking. HCM electrophysiological remodelling includes both increased inward and reduced outward currents, but their role in promoting repolarisation abnormalities remains unknown. The goal of this study is to identify key ionic mechanisms driving repolarisation abnormalities in human HCM, and to evaluate anti-arrhythmic effects of single and multichannel inward current blocks. Methods Experimental ionic current, action potential (AP) and Ca2+-transient (CaT) recordings were used to construct populations of human non-diseased and HCM AP models (n = 9118), accounting for inter-subject variability. Simulations were conducted for several degrees of selective and combined inward current block. Results Simulated HCM cardiomyocytes exhibited prolonged AP and CaT, diastolic Ca2+ overload and decreased CaT amplitude, in agreement with experiments. Repolarisation abnormalities in HCM models were consistently driven by L-type Ca2+ current (ICaL) re-activation, and ICaLblock was the most effective intervention to normalise repolarisation and diastolic Ca2+, but compromised CaT amplitude. Late Na+ current (INaL) block partially abolished repolarisation abnormalities, with small impact on CaT. Na+/Ca2+ exchanger (INCX) block effectivelyrestored repolarisation and CaT amplitude, but increased Ca2+ overload. Multichannel block increased efficacy in normalising repolarisation, AP biomarkers and CaT amplitude compared to selective block. Conclusions Experimentally-calibrated populations of human AP models identify ICaLre-activation as the key mechanism for repolarisation abnormalities in HCM, and combined INCX, INaL and ICaL block as effective antiarrhythmic therapies also able to partially reverse the HCM electrophysiological phenotype.

Published
2016
Full Text
View/download PDF

37. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure

Author

Emdin, Michele, primary, Aimo, Alberto, additional, Castiglione, Vincenzo, additional, Vergaro, Giuseppe, additional, Georgiopoulos, Georgios, additional, Saccaro, Luigi Francesco, additional, Lombardi, Carlo Mario, additional, Passino, Claudio, additional, Cerbai, Elisabetta, additional, Metra, Marco, additional, and Senni, Michele, additional

Published
2020
Full Text
View/download PDF

38. The hyperpolarization‐activated cyclic nucleotide‐gated 4 channel as a potential anti‐seizure drug target

Author

Kharouf, Qays, primary, Phillips, A. Marie, additional, Bleakley, Lauren E., additional, Morrisroe, Emma, additional, Oyrer, Julia, additional, Jia, Linghan, additional, Ludwig, Andreas, additional, Jin, Liang, additional, Nicolazzo, Joseph A., additional, Cerbai, Elisabetta, additional, Romanelli, M. Novella, additional, Petrou, Steven, additional, and Reid, Christopher A., additional

Published
2020
Full Text
View/download PDF

40. Structural Mapping of Action Potential Propagation Pathways through Healthy and Diseased Heart

Author

Lazzeri, Erica, primary, Giardini, Francesco, additional, Costantini, Irene, additional, Silvestri, Ludovico, additional, Coppini, Raffaele, additional, Ferrantini, Cecilia, additional, Mazzamuto, Giacomo, additional, Muellenbroich, Caroline, additional, Loew, Leslie M., additional, Bocchi, Leonardo, additional, Cerbai, Elisabetta, additional, Poggesi, Corrado, additional, Bishop, Martin J., additional, Pavone, Francesco S., additional, and Sacconi, Leonardo, additional

Published
2020
Full Text
View/download PDF

41. Microled Illumination Towards Liquid Crystalline Elastomers Based Cardiac Contraction Assistance

Author

Querceto, Silvia, primary, Ferrantini, Cecilia, additional, Grandinetti, Bruno, additional, Martella, Daniele, additional, Manuel Pioner, José, additional, Sybolt Wiersma, Diederik, additional, Cerbai, Elisabetta, additional, Saverio Pavone, Francesco, additional, Tesi, Chiara, additional, Poggesi, Corrado, additional, Sacconi, Leonardo, additional, and Parmeggiani, Camilla, additional

Published
2020
Full Text
View/download PDF

42. Spatiotemporal Modulation of Action Potential Duration in Intact Hearts by Sub-Thresholds Optogenetics Stimulation

Author

Biasci, Valentina, primary, Scardigli, Marina, additional, Santini, Lorenzo, additional, Coppini, Raffaele, additional, Ferrantini, Cecilia, additional, Muellenbroich, Caroline, additional, Loew, Leslie M., additional, Cerbai, Elisabetta, additional, Poggesi, Corrado, additional, Campione, Marfina, additional, Pavone, Francesco S., additional, and Sacconi, Leonardo, additional

Published
2020
Full Text
View/download PDF

43. The E258K-MYPBC3 Modelled in HCM Patient-derived Cardiomyocytes to Identify the Primary Impact of the Mutation versus the Secondary Changes Due to Cardiac Remodeling

Author

Pioner, J.M., primary, Steczina, Sonette, additional, Vitale, Giulia, additional, Mohran, Saffie, additional, Palandri, Chiara, additional, Santini, Lorenzo, additional, Querceto, Silvia, additional, Langione, Marianna, additional, Cerbai, Elisabetta, additional, Tesi, Chiara, additional, Coppini, Raffaele, additional, Ferrantini, Cecilia, additional, Poggesi, Corrado, additional, and Regnier, Michael, additional

Published
2020
Full Text
View/download PDF

47. Storia e struttura del LENS.

Author

Cerbai, Elisabetta and Schettino, Vincenzo

Subjects
STORYTELLING, QUANTUM theory, PHYSICS, LASERS, BIOLOGY
Abstract

Copyright of Il Colle di Galileo is the property of Firenze University Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results